Neoadjuvant nivolumab plus chemotherapy followed by resection for superior sulcus tumour with high PD‐L1 expression: A case report

Author:

Nakaya Takahito1ORCID,Hirai Yoshimitsu1ORCID,Akamatsu Hiroaki2,Kojima Fumiyoshi3,Iguchi Hideto1ORCID,Fusamoto Aya1,Yata Yumi1,Nagai Takahiro2,Kitahara Daiki2,Takakura Toshiaki2,Nishimura Yoshiharu1,Yamamoto Nobuyuki2

Affiliation:

1. Department of Thoracic and Cardiovascular Surgery Wakayama Medical University Wakayama Japan

2. Internal Medicine III Wakayama Medical University Wakayama Japan

3. Department of Human Pathology Wakayama Medical University Wakayama Japan

Abstract

AbstractThe standard treatment for resectable non‐small cell lung cancer (NSCLC) located in the superior sulcus is neoadjuvant chemoradiotherapy followed by highly invasive resection. Based on the results of the CheckMate 816 trial, which showed a marked improvement in the efficacy of neoadjuvant chemo‐immunotherapy, we report a case of minimally invasive resection after neoadjuvant nivolumab plus chemotherapy for superior sulcus NSCLC, resulting in a pathologic complete response. The patient was a 76‐year‐old man with a 65‐mm right superior sulcus tumour diagnosed as squamous cell carcinoma with 95% PD‐L1. After two courses of neoadjuvant nivolumab plus chemotherapy, the tumour was completely resected through an 11‐cm right lateral thoracotomy with second rib resection and first rib preservation. No residual tumour cells were observed in the specimen, and the patient had a pathologic complete response. This report represents a new treatment option for superior sulcus tumours.

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3